ACACIA PHARMA GROUP PLC financials
ACACIA PHARMA GROUP PLC
213800SLDKXWKT6E3381 | Line item | 2021 | 2020 |
|---|---|---|
| Income statement | ||
| Revenue | $1.2M | $211.0K |
| Cost of sales | $295.0K | $29.0K |
| Gross profit | $868.0K | $182.0K |
| Operating profit (EBIT) | -$66.3M | -$30.9M |
| Finance costs | $3.3M | $3.2M |
| Profit before tax | -$68.0M | -$34.1M |
| Income tax expense | -$940.0K | -$614.0K |
| Profit for the year | -$67.1M | -$33.5M |
| Total comprehensive income | -$68.9M | -$30.3M |
| Cash flow statement | ||
| Cash generated from operations | -$44.6M | -$26.1M |
| Net cash from operating activities | -$44.6M | -$25.4M |
| Net cash from investing activities | $2.0K | $41.0K |
| Net cash from financing activities | $20.7M | $56.0M |
| Proceeds from borrowings | $0 | $13.9M |
| Repayments of borrowings | $5.5M | $4.6M |
| Net change in cash | -$23.9M | $30.7M |
| Balance sheet | ||
| Total assets | $62.0M | $102.8M |
| Non-current assets | $30.8M | $52.4M |
| Right-of-use assets | $183.0K | $277.0K |
| Current assets | $31.2M | $50.4M |
| Inventories | $6.9M | $2.7M |
| Trade & other receivables | $1.1M | $461.0K |
| Cash & equivalents | $21.6M | $46.7M |
| Total equity | $25.9M | $60.5M |
| Long-term borrowings | $27.9M | $31.3M |
| Current liabilities | $8.2M | $11.1M |
| Short-term borrowings | $122.0K | $5.4M |
| Trade & other payables | $8.1M | $5.7M |
| Derived metrics | ||
| Operating margin | -5697.2% | -14654.5% |
| Net margin | -5767.3% | -15866.4% |
| Return on equity | -259.3% | -55.3% |
| Cash conversion ratio | 0.66× | 0.76× |
| Other reported items | ||
| Basic and Diluted Earnings Loss Per Share | $-0.68 | $-0.46 |
| Current Tax Assets Current | $1.7M | $574.0K |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -$1.2M | -$981.0K |
| Equity and Liabilities | $62.0M | $102.8M |
| Finance Income | $1.6M | $41.0K |
| General and Administrative Expense | $31.1M | $11.6M |
| Impairment Loss Recognised In Profit Or Loss Intangible Assets Other Than Goodwill | $13.0M | $0 |
| Income Taxes Refund Classified As Operating Activities | $47.0K | $740.0K |
| Increase Decrease Through Exercise of Options | $318.0K | $10.0K |
| Increase Decrease Through Sharebased Payment Transactions | $3.8M | $2.7M |
| Increase Decrease Through Treasury Share Transactions | $65.0K | $0 |
| Intangible Assets Other Than Goodwill | $30.6M | $52.2M |
| Interest Received Classified As Investing Activities | $2.0K | $41.0K |
| Issued Capital | $2.8M | $2.5M |
| Liabilities | $36.1M | $42.4M |
| Merger Reserve | -$106.6M | -$106.6M |
| Other Comprehensive Income | -$1.8M | $3.2M |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | -$1.8M | $3.2M |
| Payments For Share Issue Costs | $2.7M | $3.5M |
| Proceeds From Issue of Ordinary Shares | $33.2M | $51.9M |
| Research and Development Expense | $4.1M | $99.0K |
| Reserve of Exchange Differences On Translation | $153.0K | $2.0M |
| Reserve of Sharebased Payments | $10.3M | $6.5M |
| Retained Earnings | -$69.4M | -$2.3M |
| Sales and Marketing Expense | $32.0M | $19.4M |
| Share Issue Related Cost | $2.7M | $3.5M |
| Share Premium | $188.6M | $158.4M |
| Treasury Shares | $25.0K | $41.0K |
Every line item above is a fact tagged in ACACIA PHARMA GROUP PLC's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (USD), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.